

4121-171

Sir:

A review of the Filing Receipt in the above-identified patent application, as received in the undersigned attorney's office, has revealed the presence of an error in the title.

The appropriate title is as follows:

**DIAGNOSTIC CONJUGATE USEFUL FOR INTRACELLULAR IMAGING AND FOR
DIFFERENTIATING BETWEEN TUMOR- AND NON-TUMOR CELLS**

Applicants note that characters in the title for the subject U.S. patent application require proper spacing to ensure that the scope and substance of the invention is represented properly.

Request hereby is made for issue of a Corrected Filing Receipt for the subject U.S. patent application.

The error has been annotated on the accompanying copy of the Filing Receipt.

Respectfully submitted,



Steven J. Hultquist
Reg. No. 28,021
Attorney for Applicants

INTELLECTUAL PROPERTY/
TECHNOLOGY LAW
Phone: (919) 419-9350
Fax: (919) 419-9354
Attorney File No.: 4121-171

Enclosures:
Copy of February 17, 2005 Filing Receipt [2 pages]

<p>The USPTO is hereby authorized to charge any deficiency or credit any overpayment of fees properly payable for this document to Deposit Account No. 08-3284</p>
--



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1430
 Alexandria, Virginia 22313-1430
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/502,442	10/04/2004	1645	525	4121-171	5	19	1

CONFIRMATION NO. 3755

Steven J Hultquist
 Intellectual Property/Technology Law
 P O Box 14329
 Research Triangle Park, NC 27709

10/24/2004

FILING RECEIPT



OC000000015176255

Date Mailed: 02/17/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Klaus Braun, Sandhausen, GERMANY;
 Jurgen Debus, Heidelberg, GERMANY;
 Jurgen Jenne, Mannheim, GERMANY;
 Rudiger Pipkorn, Heidelberg, GERMANY;
 Ralf Rastert, Mosbach, GERMANY;
~~Waldemar Waldeck, Laudenbach, GERMANY;~~
 Isabell Braun, Colbe-Burgeln, GERMANY;

Power of Attorney:

Steven Hultquist-28021
 Marianne Fuierer-39983
 Tristan Fuierer-52926

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/EP03/00609 01/22/2003

Foreign Applications

EUROPEAN PATENT OFFICE (EPO) 02001506.1 01/22/2002

Projected Publication Date: 05/26/2005

Non-Publication Request: No

Early Publication Request: No

**** SMALL ENTITY ****

Title

Diagnostic conjugate useful for intracellular imaging and for differentiating between tumor and non-tumor cells

space

Preliminary Class

435

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).